Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia

beta-Lactam/beta-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum beta-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The...

Descripción completa

Detalles Bibliográficos
Autores: Gudiol, C, Royo-Cebrecos, C, Abdala, E, Akova, M, Alvarez, R, Maestro-de La Calle, G, Cano, A, Cervera, C, Clemente, WT, Martin-Davila, P, Freifeld, A, Gomez, L, Gottlieb, T, Gurgui, M, Herrera, F, Manzur, A, Maschmeyer, G, Meije, Y, Montejo, M, Peghin, M, Rodriguez-Bano, J, Ruiz-Camps, I, Sukiennik, TC, Tebe, C, Carratala, J
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p14168
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14168
https://europepmc.org/articles/pmc5527609
Access Level:acceso abierto
Palabra clave:ESBLs
bloodstream infection
neutropenia
beta-lactam/beta-lactamase inhibitors
mortality
Descripción
Sumario:beta-Lactam/beta-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum beta-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.

Similares en LA Referencia